Drugs derived from activated protein C may limit ischemia and reperfusion injury, study suggests

A University of South Florida Health preclinical study offers molecular insight into how activated protein C (APC) may improve aging patients' tolerance to reperfusion injury – a potentially adverse effect of treatment for ischemic heart disease.